Strategies for Addressing Treatment Challenges and Health Inequities in IBD

Join us to hear from renowned gastroenterology experts to gain insights on recent advances in IBD treatment, strategies for individualizing care, and addressing challenges of health inequity for patients with IBD.

Agenda

Times are PT

6:30 PM Welcome and Program Overview

6:35 PM Recent Advances in Treatment

6:55 PM Strategies for Individualizing Treatment

7:15 PM Reducing the Impact of Health Inequities

7:30 PM Case Discussion and Question and Answer Session

7:55 PM Closing remarks

8:00 PM Adjournment

Events

Date / Time
Event Details

Faculty

Program Chair
Anita Afzali, MD, MPH, MHCM, FACG, AGAF

Professor of Clinical Medicine
Division of Digestive Diseases
Executive Vice Chair, Department of Internal Medicine
Associate Chief Medical Officer
University of Cincinnati, UC Health System
Cincinnati, Ohio

Faculty
David Hudesman, MD

Associate Professor of Medicine
Gastroenterology
NYU School of Medicine
Co-Director
Inflammatory Bowel Disease Center at NYU Langone
Gastroenterology
NYU Langone Health
New York, New York

Faculty
Millie D. Long, MD, MPH, FACG, AGAF

Professor of Medicine
Director,
Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Program Overview
CE-certified education featuring a live 90-minute satellite symposium with downloadable slides and an enduring Webcast. The goal of this activity is to improve learners’ knowledge and competence regarding recent advances in therapy, individualized IBD management, and health inequities affecting patients with IBD.

Goal Statement
The goal of this activity is to improve learners’ knowledge and competence regarding recent advances in therapy, individualized IBD management, and health inequities affecting patients with IBD.

Target Audience
This program is intended for primary care professionals, including physicians, nurse practitioners, physician associates/assistants, and other healthcare professionals who manage patients with IBD.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Detail recent advances in the IBD treatment landscape
  • Apply strategies to individualize treatment plans for patients with CD and UC
  • Implement strategies to reduce health inequities among patients with IBD

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Physician Associate/Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.